TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38148468
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation for 15 minutes after internal mammary artery harvesting
Study: 38148664
Drug: Blood lactate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood lactate, arginine, and proline metabolism.
Study: 38148846
Drug: 150 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min/wk of moderate-intensity aerobic exercise (low-dose)
Study: 38148846
Drug: 300 min/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 min/wk of moderate-intensity aerobic exercise (high-dose)
Study: 38149073
Drug: Kombucha enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kombucha enriched with inulin (2.53 g/220 mL) and vitamins (B1 - 0.59 mg, B2 - 0.55 mg, B3 - 5.9 mg, B6 - 0.7 mg, folic acid - 81.4 μg/220 mL)
Study: 38149099
Drug: PyroH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PyroH plus chemotherapy
Study: 38149099
Drug: HP plus
Normalized name: Aluris HP Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP plus chemotherapy
Study: 38149261
Drug: Lived experience
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lived experience of receiving medical treatment for a mental illness
Study: 38149403
Drug: Intravenous fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosphenytoin 18 mg/kg (high dose)
Study: 38149403
Drug: Intravenous fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosphenytoin 12 mg/kg (low dose)
Study: 38149948
Drug: CD30.CAR-T therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD30.CAR-T therapy
Study: 38150009
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (900 mg/day)
Study: 38150126
Drug: Merged ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merged ML model utilizing gaze, eye landmarks, head position, and facial landmarks
Study: 38150232
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for opioid use disorder (MOUD) treatment offered at intake, throughout incarceration, and upon release.
Study: 38150232
Drug: Sample contractual
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sample contractual language for medical provider proposals to integrate MOUD treatment.
Study: 38150256
Drug: Topical 1.62%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.62% testosterone gel
Study: 38150260
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care with higher doses of GDMT
Study: 38150260
Drug: Medium doses
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium doses of GDMT
Study: 38150260
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of GDMT
Study: 38150260
Drug: Higher GDMT
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher GDMT doses at week 2
Study: 38150310
Drug: Remote monitoring,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote monitoring, monthly digital registration of patient-reported outcomes
Study: 38151376
Drug: Instrumental Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Study: 38151376
Drug: Basic Activities
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Study: 38151388
Drug: epcoritamab monotherapy
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epcoritamab monotherapy
Study: 38152412
Drug: ixoberogene soroparvovec
Normalized name: Ixoberogene soroparvovec
DrugBank: Ixoberogene soroparvovec (DB16817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixoberogene soroparvovec (ixo-vec) gene therapy
Study: 38152462
Drug: Psilocybin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (10, 20, 30 mg/70 kg)
Study: 38152697
Drug: Onalespib (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onalespib (260 mg/m) + Paclitaxel (standard dose)
Study: 38152962
Drug: Reteplase 12+12
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase 12+12 mg
Study: 38152962
Drug: Reteplase 18+18
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase 18+18 mg
Study: 38153320
Drug: Repeat treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat treatment courses with Zuranolone
Study: 38154074
Drug: Prazosin 2.5
Normalized name: prazosin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 2.5 mg/day for 7 days, then 5 mg/day for 21 days
Study: 38154083
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (hemoglobin threshold 7.0 g/dL)
Study: 38154083
Drug: Conservative transfusion
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative transfusion strategy (hemoglobin threshold 5.5 g/dL)
Study: 38154287
Drug: SPACE-Standard (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPACE-Standard (12 weekly telehealth sessions)
Study: 38154616
Drug: Ivermectin (0.3-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (0.3-0.4 mg/kg, orally on an empty stomach once daily for three days)
Study: 38154902
Drug: One of
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of five different single-injection techniques/combination of techniques for regional/neuraxial analgesia
Study: 38155164
Drug: Multimedia-based hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimedia-based hormone therapy information program (HTIP)
Study: 38155512
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy for borderline resectable pancreatic cancer
Study: 38155512
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy for locally advanced pancreatic cancer
Study: 38155668
Drug: Vibroacoustic pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibroacoustic pulmonary therapy using the 'VibroLung' device in 'ARDS' mode
Study: 38155668
Drug: Vibroacoustic pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibroacoustic pulmonary therapy using the 'VibroLung' device in 'Pneumonia' mode
Study: 38155784
Drug: EndoPatch (endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoPatch (endovascular double-disc implant)
Study: 38155784
Drug: Conventional endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional endovascular treatment techniques
Study: 38156601
Drug: Low-dose quadruple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quadruple therapy (LDQT)
Study: 38157190
Drug: Ibrutinib plus
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib plus venetoclax (560 mg ibrutinib and 400 mg venetoclax after a 5-week ramp-up from 20 mg, once daily for up to 104 weeks)
Study: 38157348
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg IV QID for seven days
Study: 38157348
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg (single dose)
Study: 38157499
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21)
Study: 38157499
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90)
Study: 38157986
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg folic acid supplement
Study: 38157986
Drug: 0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg folic acid supplement (control)
Study: 38158089
Drug: Octreotide 40-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 40-mg long-acting release intramuscular every 28 days
Study: 38158089
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (including endoscopic therapy)
Study: 38158583
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin therapy using a connected insulin pen
Study: 38158919
Drug: Albuminuria (mild:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuminuria (mild: 10-29 mg/g, moderate/severe: ≥30 mg/g)
Study: 38159003
Drug: Chitotriosidase (CHIT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitotriosidase (CHIT) level > 171 nmol/h/mL
Study: 38159266
Drug: Lorpucitinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorpucitinib (30 mg daily, 30 mg every 12 hours, or 75 mg every 12 hours)
Study: 38159266
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg every 12 hours)
Study: 38159266
Drug: Lorpucitinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorpucitinib (75 mg single dose)
Study: 38159266
Drug: Lorpucitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorpucitinib (all doses)
Study: 38159938
Drug: Secondary cytoreductive
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreductive surgery followed by platinum based chemotherapy
Study: 38159946
Drug: Establishment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Establishment of biological sample bank
Study: 38159958
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention, consisting of 10 sessions.
Study: 38160049
Drug: HDM sublingual
Normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM sublingual immunotherapy (SLIT)-tablets
Study: 38160917
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg subcutaneously every 2 weeks
Study: 38162283
Drug: Community-based delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based delivery of HIV services including testing, antiretroviral therapy, treatment monitoring and adherence support, family planning, syndromic management of STIs, menstrual health management, condoms, and HIV prevention and general health counselling.
Study: 38162492
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) alone (standard treatment)
Study: 38162999
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g sustained-release L-arginine 3 times/d (4.5 g/d) for 4 weeks
Study: 38163317
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (iFCR with 2-year I-M)
Study: 38163585
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks for up to 144 weeks (∼3 years)
Study: 38163912
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for soil-transmitted helminth infections (STH)
Study: 38164441
Drug: FUEL intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FUEL intervention consisting of weekly online lectures and individual athlete-centered nutrition counseling every other week for sixteen weeks.
Study: 38164586
Drug: Radioligand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy agent (specific agent not mentioned)
Study: 38164752
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard blood pressure treatment)
Study: 38164757
Drug: XTX101 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XTX101 monotherapy
Study: 38164757
Drug: XTX101 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: XTX101 in combination with anti-PD-1 mAb
Study: 38165016
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) treatment combined with zoledronic acid (ZA)
Study: 38165027
Drug: m-health tool
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-health tool (pre-programmed tablet with weighing scale and interactive education about HF self-care)
Study: 38165333
Drug: IV nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV nipocalimab 5 mg/kg Q4W
Study: 38165333
Drug: IV nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV nipocalimab 30 mg/kg Q4W
Study: 38165333
Drug: IV nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV nipocalimab 60 mg/kg Q2W
Study: 38165333
Drug: IV nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV nipocalimab 60 mg/kg single dose
Study: 38165683
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with bevacizumab (Cohort 1A)
Study: 38165683
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel without bevacizumab (Cohort 1B)
Study: 38165683
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2)
Study: 38166187
Drug: Quantum molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quantum molecular resonance treatment with Rexon-Eye device, once per week for 4 weeks
Study: 38166598
Drug: Emergence agitation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergence agitation and high-dose opioid consumption
Study: 38166647
Drug: Regorafenib monotherapy
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib monotherapy
Study: 38166647
Drug: Regorafenib combined
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib combined with immune-checkpoint inhibitors
Study: 38166710
Drug: Levetiracetam 1000
Normalized name: levetiracetam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 1000 mg IV every 12 hours
Study: 38166913
Drug: Acetazolamide (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (twice daily, 2 days)
Study: 38166913
Drug: Rapid-Ripc (RIPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-Ripc (RIPC four times daily, 3 days)
Study: 38166913
Drug: Ripc (RIPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ripc (RIPC twice daily, 6 days)
Study: 38167019
Drug: Adalimumab with
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab with methotrexate co-treatment
Study: 38167022
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiomics features and serum β-D-glucan levels
Study: 38167064
Drug: 5% losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% losartan potassium loaded in ethosomal gel
Study: 38167064
Drug: 10% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% triamcinolone acetonide (intralesional injections)
Study: 38167115
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) administered via continuous intravenous administration for 7 days
Study: 38167115
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) administered via continuous intravenous administration for 7 days
Study: 38167178
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS (60 min duration, placebo treatment for 10 sessions)
Study: 38167204
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion intervention group receiving four weekly 1-h sessions with induction and hypnosis
Study: 38167204
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control group receiving four weekly 1-h sessions of induction and mindfulness
Study: 38167503
Drug: Immunotherapy (ipilimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (ipilimumab plus nivolumab) followed by BRAF/MEK inhibition (encorafenib plus binimetinib)
Study: 38167503
Drug: 8-week induction
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week induction course of targeted therapy (encorafenib plus binimetinib) followed by immunotherapy
Study: 38167503
Drug: Immunotherapy (ipilimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (ipilimumab plus nivolumab)
Study: 38167806
Drug: Chemotherapy SAP
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy SAP alone (SAP)
Study: 38167882
Drug: Bipolar androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bipolar androgen therapy (BAT) with nivolumab
Study: 38167937
Drug: Chemotherapy (SOX/XELOX)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (SOX/XELOX)
Study: 38168442
Drug: 5% 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-Fluorouracil (5-FU) cream, 2g self-administered intravaginally every other week for eight applications.
Study: 38169574
Drug: Low-dose QiShen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose QiShen YiQi Dripping Pills (QSYQ)
Study: 38169574
Drug: High-dose QiShen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose QiShen YiQi Dripping Pills (QSYQ)
Study: 38169790
Drug: SW-BIC-213 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SW-BIC-213 (25 μg)
Study: 38170033
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily with ASA 80 mg once daily
Study: 38170033
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily with ASA 80 mg once daily
Study: 38170185
Drug: Ketamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine treatment (dosage and duration not available)
Study: 38170256
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium valproate (SV) applied twice daily
Study: 38170256
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone furoate lotion applied twice daily
Study: 38170256
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium valproate (SV) and topical steroids
Study: 38170741
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (INO) at a maximum tolerated dose (MTD) of 0.6 mg/m2, administered on day 1 of 28-day cycles.
Study: 38171034
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of Ca-HMB with resistance training (3 sessions/week)
Study: 38171633
Drug: Chronotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy in addition to Treatment as Usual (TAU)
Study: 38171926
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy vectors and strategies for liver-targeting
Study: 38171926
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy administration in a fibrotic liver
Study: 38172458
Drug: Alveolar ridge
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alveolar ridge splitting (ARS) with guided bone regeneration (GBR) using simvastatin (SMV) gel mixed bone graft and a barrier membrane with simultaneous implant placement
Study: 38172458
Drug: Guided bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided bone regeneration (GBR) without simvastatin (SMV) gel
Study: 38172930
Drug: CDSS-OPTIMED intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDSS-OPTIMED intervention (software program providing weekly personalized medication recommendations)
Study: 38174147
Drug: LCPT (Life
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT (Life cycle pharma tacrolimus) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight.